{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:12:06Z","timestamp":1784830326987,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T00:00:00Z","timestamp":1285545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Smallpox is an acute disease caused by infection with variola virus that has had historic effects on the human population due to its virulence and infectivity. Because variola remains a threat to humans, the discovery and development of novel pox therapeutics and vaccines has been an area of intense focus. As variola is a uniquely human virus lacking a robust animal model, the development of rational therapeutic or vaccine approaches for variola requires the use of model systems that reflect the clinical aspects of human infection. Many laboratory animal models of poxviral disease have been developed over the years to study host response and to evaluate new therapeutics and vaccines for the treatment or prevention of human smallpox. Rabbitpox (rabbitpox virus infection in rabbits) is a severe and often lethal infection that has been identified as an ideal disease model for the study of poxviruses in a non-rodent species. The aerosol infection model (aerosolized rabbitpox infection) embodies many of the desired aspects of the disease syndrome that involves the respiratory system and thus may serve as an appropriate model for evaluation of antivirals under development for the therapeutic treatment of human smallpox. In this review we summarize the aerosol model of rabbitpox, discuss the development efforts that have thus far used this model for antiviral testing, and comment on the prospects for its use in future evaluations requiring a poxviral model with a focus on respiratory infection.<\/jats:p>","DOI":"10.3390\/v2092096","type":"journal-article","created":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T11:23:33Z","timestamp":1285586613000},"page":"2096-2107","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents"],"prefix":"10.3390","volume":"2","author":[{"given":"Chad J.","family":"Roy","sequence":"first","affiliation":[{"name":"Infectious Disease Aerobiology, Microbiology Division, Tulane National Primate Research Center, 18703 Three Rivers Road, Covington, Louisiana, USA"},{"name":"Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Voss","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/medicina43040034","article-title":"Public health and bioterrorism: Renewed threat of anthrax and smallpox","volume":"43","author":"Wallin","year":"2007","journal-title":"Medicina (Kaunas)"},{"key":"ref_2","first-page":"505","article-title":"Experimenteel onderzoek van Kon-ijnensterfte door een filteebaar virus","volume":"69","author":"Jansen","year":"1942","journal-title":"Tijdschr. Diergeneesk."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3181\/00379727-30-6724","article-title":"A pandemic of rabbit-pox","volume":"30","author":"Greene","year":"1933","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_4","first-page":"441","article-title":"Rabbit pox II","volume":"60","author":"Greene","year":"1934","journal-title":"Pathology of the epidemic disease. J. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1099\/vir.0.81331-0","article-title":"Complete coding sequences of the rabbitpox virus genome","volume":"86","author":"Li","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S0022172400070959","article-title":"A poxvirus antigen associated with pathogenicity for rabbits","volume":"89","author":"Rondle","year":"1982","journal-title":"J. Hyg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(61)90969-2","article-title":"Value of serotherapy in a virus disease (rabbit pox)","volume":"2","author":"Boulter","year":"1961","journal-title":"Lancet"},{"key":"ref_8","first-page":"295","article-title":"Protection against poxviruses","volume":"62","author":"Boulter","year":"1969","journal-title":"Proc. R. Soc. Med."},{"key":"ref_9","first-page":"453","article-title":"Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies","volume":"47","author":"Westwood","year":"1966","journal-title":"Brit. J. Exp. Pathol."},{"key":"ref_10","first-page":"466","article-title":"Experimental respiratory infection with poxviruses. II. Pathological studies","volume":"47","author":"Lancaster","year":"1966","journal-title":"Brit. J. Exp. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1700850102","article-title":"Rabbit pox: An experimental study of the pathways of infection in rabbits","volume":"85","author":"Bedson","year":"1963","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/viro.1994.1347","article-title":"The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation","volume":"202","author":"Ali","year":"1994","journal-title":"Virology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0042-6822(80)90075-6","article-title":"The white pock mutants of rabbit poxvirus. I. Spontaneous host range mutants contain deletions","volume":"102","author":"Moyer","year":"1980","journal-title":"Virology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00568973","article-title":"The nature of naturally occurring mutations in the hemagglutinin gene of vaccinia virus and the sequence of immediately adjacent genes","volume":"5","author":"Brown","year":"1991","journal-title":"Virus Genes"},{"key":"ref_16","first-page":"S34","article-title":"Rabbitpox: An Aerosol Model for the Study of Aerosolized Poxviruses","volume":"43","author":"Roy","year":"2004","journal-title":"J. Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2008.03.005","article-title":"Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model","volume":"79","author":"Nalca","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2009.06.105","article-title":"Evaluation of the efficacy of modified vaccinia Ankara (MVA)\/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model","volume":"27","author":"Garza","year":"2009","journal-title":"Vaccine"},{"key":"ref_19","unstructured":"Roy, C.J. (2010). Tulane University, New Orleans, LA, USA, Unpublished work."},{"key":"ref_20","first-page":"511","article-title":"Sampling rabbit pox aerosols of natural origin","volume":"68","author":"Thomas","year":"1970","journal-title":"J. Hyg. (Lond.)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/jam.1994.7.315","article-title":"Selective deposition of inhaled aerosols to mechanically ventilated rabbits","volume":"7","author":"Dahlback","year":"1994","journal-title":"J. Aerosol. Med."},{"key":"ref_22","first-page":"831","article-title":"Pathology of aerosolized rabbitpox virus infection in rabbits","volume":"43","author":"Roy","year":"2006","journal-title":"Vet. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/rmv.439","article-title":"Therapeutic potential of nucleoside\/nucleotide analogues against poxvirus infections","volume":"14","author":"Neyts","year":"2004","journal-title":"Rev. Med. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.14.2.382-397.2001","article-title":"Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections","volume":"14","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00008-6","article-title":"Cidofovir in the treatment of poxvirus infections","volume":"55","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0166-3542(02)00197-3","article-title":"Therapy and short-term prophylaxis of poxvirus infections: Historical background and perspectives","volume":"57","author":"Neyts","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0166-3542(02)00199-7","article-title":"A review of compounds exhibiting anti-orthopoxvirus activity in animal models","volume":"57","author":"Smee","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF01702566","article-title":"Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants","volume":"6","author":"Boyle","year":"1992","journal-title":"Virus Genes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(02)00198-5","article-title":"In vitro activity of potential anti-poxvirus agents","volume":"57","author":"Kern","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2003.07.001","article-title":"The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates","volume":"49","author":"Hartings","year":"2004","journal-title":"J. Pharmacol. Toxicol. Method."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Swearengen, J.L. (2005). Biodefense: Research Methodology and Animal Models, CRC Press. Chapter 5.","DOI":"10.1201\/9781420038118"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1749-6632.1965.tb12546.x","article-title":"The laboratory and clinical assessment of an isothiazole thiosemicarbazone (M 2 b 7714) against pox viruses","volume":"130","author":"Rao","year":"1965","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2006.02.010","article-title":"In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections","volume":"71","author":"Quenelle","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0165-6147(02)02091-6","article-title":"Cidofovir in the therapy and short-term prophylaxis of poxvirus infections","volume":"23","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkh286","article-title":"Antiviral prophylaxis of smallpox","volume":"54","author":"Bray","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/9\/2096\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:03:27Z","timestamp":1760220207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/9\/2096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,27]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2010,9]]}},"alternative-id":["v2092096"],"URL":"https:\/\/doi.org\/10.3390\/v2092096","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,27]]}}}